Immunicum

• Placement of 33.2 million new shares at a subscription price of SEK 4.25 per share, generating gross proceeds of approximately SEK 141.2 million
• Immunicum intends to use the net proceeds to fund the continuation of ongoing clinical trials and preparations for clinical pipeline expansion, expansion of process development activities, preclinical research activities, and general corporate purposes
• The company’s largest shareholder Van Herk subscribed for its pro rata share (43.36%) and the second largest shareholder AP4 subscribed for an amount of circa SEK 52.8 million, thereby bringing its post-transaction stake in Immunicum to 9.99%
• In 2021 year to date, Kempen & Co has already executed 16 transactions for European life sciences companies

Immunicum is a clinical-stage biopharmaceutical company developing off-the-shelf immune primers based on allogeneic dendritic cell biology to treat blood-borne and solid tumors. The company addresses key challenges in cancer therapy being difficult-to-treat tumors and tumors with a high risk of recurrence through unique approaches of intratumoral priming and cancer relapse vaccination.

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Lead Manager in Molecular Partners’ USD 63.8 million Initial Public Offering on Nasdaq
• Joint Bookrunner in the SEK 301m Capital Increase by Q-linea
• Co-Manager in the USD 176 million Nasdaq Initial Public Offering by Achilles Therapeutics 
• Joint Bookrunner in the €30 million Capital Increase by GenSight Biologics
• Lead Manager in the USD 101 million Nasdaq Initial Public Offering by LAVA Therapeutics
• Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
• Joint Bookrunner in the SEK 1.1 billion capital increase by Oncopeptides
• Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
• Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
• Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
• Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
• Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
• Bookrunner in the USD 518 million US Public Offering by CureVac
• Lead Manager in the USD 120 million US Public Offering by Merus 
• Financial Adviser to DCprime in its merger with Immunicum 
• Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
• Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
• Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
• Lead Manager in the USD 95.1 million Nasdaq Initial Public Offering by Galecto
• Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
• Bookrunner in the USD 245 million Nasdaq Initial Public Offering by CureVac
• Co-Manager in the USD 49.0 million US Public Offering by Centogene
• Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
• Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
• Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
• Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp, thereby becoming a Nasdaq listed company and securing USD 253 million
• Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
• Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
• Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
• Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
• Co-Manager in the USD 862 million Global Offering by argenx
• Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides